Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $190 million, representing an 11% year-over-year growth, while full-year revenue reached $727 million, a 10% increase over 2024 [8][23] - Adjusted gross profit improved by $5.8 million, or 7% year-over-year, with adjusted EBITDA at $13.4 million, up 10% [20] - Cash flow from operations was positive at $1 million for Q4, with total cash at $160 million, slightly down from Q3 [22] Business Line Data and Key Metrics Changes - Clinical business revenue increased by 16% year-over-year in Q4, driven by effective commercial strategies and a 23% growth in NGS revenue [8][20] - Non-clinical revenue declined by over 25% in Q4, consistent with expectations [20] - Average revenue per clinical test (AUP) increased by 5% year-over-year, with a sequential increase of 3% from Q3 [21] Market Data and Key Metrics Changes - The company holds a leadership position in the hematology testing market with over 25% share across diagnostics and therapy selections [10] - Approximately 40% of active pathologists and oncologists ordered five or more tests from the company during the year, indicating significant market penetration [11] Company Strategy and Development Direction - The company aims to drive growth through strategic investments in NGS and MRD initiatives, with a focus on expanding its oncology sales force [29] - The launch of the RaDaR ST MRD assay is set for the end of the month, with plans to expand the sales force to penetrate the head and neck market [13][14] - The company is also focusing on enhancing operational efficiencies through technology and automation investments [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue growth in 2026, projecting revenues between $793 million and $801 million, with a focus on high-margin modalities [25][27] - The company anticipates modest revenue contributions from RaDaR ST in 2026, with expectations for accelerated growth in 2027 and beyond [14][25] - Management acknowledged potential impacts from extreme weather on Q1 volumes but remains optimistic about meeting full-year guidance [26] Other Important Information - The company has submitted additional solid tumor cancer indications for MolDX approval, which could double the market opportunity for RaDaR ST testing [14] - The PanTracer portfolio is expanding, with strong growth in PanTracer Tissue tests and the recent launch of PanTracer Pro [17] Q&A Session Summary Question: Can you provide specifics on the RaDaR ST launch and sales rep expansion? - Management confirmed the full launch of RaDaR ST at the end of the month, focusing on head and neck and breast cancer indications, with an initial expansion of sales reps dedicated to these areas [34][38] Question: What is the impact of exiting low-value business on clinical volume? - Management indicated that exiting low-value contracts would lead to higher AUP growth, with expectations for AUPs in the upper single-digit range and volume growth in the lower- to mid-single-digit range [45][46] Question: What are the expectations for pharma ordering in 2026? - Management anticipates modest erosion in the pharma business for 2026, with RaDaR ST expected to be a key growth driver [70][74] Question: Can you discuss the LIMS rollout and its impact on earnings? - The LIMS integration is ongoing, with benefits expected to materialize in 2027 and 2028, while operational efficiencies will begin to show in 2026 [60][62]